
## **Stephane Chauvie**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9285611/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with Râ€CHOP14: A SAKK 38/07 trial postâ€hoc analysis. Hematological Oncology, 2022, 40, 12-22.	1.7	13
2	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. Journal of Clinical Oncology, 2022, 40, 729-739.	1.6	34
3	A prognostic model integrating PETâ€derived metrics and image texture analyses with clinical risk factors from GOYA. EJHaem, 2022, 3, 406-414.	1.0	6
4	The role of medical physicists in clinical trials across Europe. Physica Medica, 2022, 100, 31-38.	0.7	2
5	Standardization of <sup>18</sup> F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2021, 39, 116-125.	1.6	85
6	Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1005-1015.	6.4	35
7	Cualificación de fantomas 18F para ensayos clÃnicos con imagen PET/TC-18F-FDG adoptada por GELTAMO (Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea). Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 149-154.	0.0	0
8	The 18â€ <sup>−</sup> F phantom clinical trials qualification for 18F-FDG-PET scanning adopted by GELTAMO (Grupo) Tj ETQc Imagen Molecular, 2021, 40, 149-154.	0 0 0 rgB1 0.2	[ /Overlock 1 2
9	Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. Annals of Hematology, 2021, 100, 2547-2556.	1.8	1
10	Myocardial Metabolic Response Predicts Chemotherapy Curative Potential on Hodgkin Lymphoma: A Proof-of-Concept Study. Biomedicines, 2021, 9, 971.	3.2	1
11	Lesion Dissemination in Baseline PET/CT (D-MAX) and IPS Score Predict ABVD Treatment Outcome in PET-2 Negative Advanced-Stage Hodgkin Lymphoma Patients Enrolled in the Prospective GITIL/FIL HD0607 Trial. Blood, 2021, 138, 2443-2443.	1.4	3
12	The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PETâ€2â€adapted HD0607 trial. Cancer Medicine, 2020, 9, 8735-8746.	2.8	10
13	Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. Journal of Clinical Oncology, 2020, 38, 3905-3913.	1.6	36
14	Artificial intelligence and radiomics enhance the positive predictive value of digital chest tomosynthesis for lung cancer detection within SOS clinical trial. European Radiology, 2020, 30, 4134-4140.	4.5	17
15	The impact of time-of-flight, resolution recovery, and noise modelling in reconstruction algorithms in non-solid-state detectors PET/CT scanners: – multi-centric comparison of activity recovery in a 68Ge phantom. Physica Medica, 2020, 75, 85-91.	0.7	3
16	Learned Deep Radiomics for Survival Analysis with Attention. Lecture Notes in Computer Science, 2020, , 35-45.	1.3	1
17	Monitoring response in lymphomas: qualitative, quantitative, or what else?. Leukemia and Lymphoma, 2019, 60, 302-308.	1.3	5
18	CONSOLIDATION RADIOTHERAPY COULD BE OMITTED IN ADVANCED HODGKIN LYMPHOMA WITH LARGE NODAL MASS IN COMPLETE METABOLIC RESPONSE AFTER ABVD. FINAL ANALYSIS OF THE RANDOMIZED HD0607 TRIAL. Hematological Oncology, 2019, 37, 147-148.	1.7	3

#	Article	IF	CITATIONS
19	RADIOMICS INCREASE THE PROGNOSTIC VALUE OF CLINICAL AND PET RISK FACTORS IN DLBCL: RESULTS FROM THE PHASE 3 GOYA STUDY. Hematological Oncology, 2019, 37, 52-53.	1.7	0
20	The role of PET/CT in the modern treatment of Hodgkin lymphoma. Cancer Treatment Reviews, 2019, 77, 44-56.	7.7	51
21	RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI Hematological Oncology, 2019, 37, 153-154.	1.7	19
22	INTERIM ANALYSIS OF CENTRAL REVIEW OF END-OF-THERAPY PET IN FOLL12 TRIAL FOR FOLLICULAR LYMPHOMA. Hematological Oncology, 2019, 37, 393-393.	1.7	1
23	PS1237 DOSE DENSE ABVD (DDâ€ABVD) AS FIRST LINE THERAPY IN EARLYâ€STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTIâ€CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI. HemaSphere, 2019, 3, 563-564.	2.7	0
24	DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVORABLE HODGKIN LYMPHOMA (HD): RESULTS OF A PHASE II, PROSPECTIVE STUDY BY FONDAZIONE ITALIANA LINFOMI. Hematological Oncology, 2019, 37, 291-292.	1.7	2
25	PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma. PET Clinics, 2019, 14, 317-329.	3.0	16
26	A core laboratory approach to large-scale radiomics and machine-learning prediction of DLBCL outcomes after first-line treatment using results from the phase III GOYA study Journal of Clinical Oncology, 2019, 37, e19042-e19042.	1.6	0
27	A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA. Blood, 2019, 134, 883-883.	1.4	1
28	Dual-point FDG-PET/CT for treatment response assessment in Hodgkin lymphoma, when an FDG-avid lesion persists after treatment. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 176-184.	1.0	5
29	Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1463-1464.	6.4	19
30	Automatic liver detection and standardised uptake value evaluation in whole-body Positron Emission Tomography/Computed Tomography scans. Computer Methods and Programs in Biomedicine, 2018, 156, 47-52.	4.7	5
31	Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian) Tj ETQq1 1 0 712-719.	).784314 6.4	rgBT /Over or 95
32	Metabolic Tumor Volume Metrics in Lymphoma. Seminars in Nuclear Medicine, 2018, 48, 50-66.	4.6	75
33	280. VATS (Video Assisted Thoracoscopic Surgery) with radiological guidance in hybrid operating room: Technique standardization, organizational aspects and dose optimization. Physica Medica, 2018, 56, 233-234.	0.7	0
34	356. ZeroDose: An automatic tool for exposure indexes retrieval from images stored in PACS system. Physica Medica, 2018, 56, 275-276.	0.7	0
35	[OA143] Application of new algorithms in PET image reconstruction: Preliminary results. Physica Medica, 2018, 52, 54-55.	0.7	0
36	326. PET scanner qualification for clinical trial: Comparison between Italian and worldwide experience. Physica Medica, 2018, 56, 260.	0.7	0

#	Article	IF	CITATIONS
37	Abstract ID: 375 Quantitative imaging in nuclear medicine. Physica Medica, 2018, 56, 284.	0.7	0
38	Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. Journal of Clinical Oncology, 2018, 36, 454-462.	1.6	169
39	281. Prostate artery embolization of benign prostate hyperplasia: Technical and dosimetric aspects. Physica Medica, 2018, 56, 234.	0.7	0
40	241. Radiation risk due to medical imaging in long living patients: the case of Hodgkin lymphoma. Physica Medica, 2018, 56, 210-211.	0.7	0
41	Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials. Blood, 2018, 132, 257-257.	1.4	20
42	Comparison of digital tomosynthesis and computed tomography for lung nodule detection in SOS screening program. Radiologia Medica, 2017, 122, 568-574.	7.7	8
43	Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1622-1635.	6.4	91
44	Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal Bâ€cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Groupâ€37 study. Hematological Oncology, 2017, 35, 548-553.	1.7	22
45	The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients—the Polish Lymphoma Research Group (PLRG) Observational Study. Annals of Oncology, 2017, 28, 3051-3057.	1.2	16
46	Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, , .	0.7	3
47	The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials. Biomedicines, 2016, 4, 26.	3.2	8
48	Recent developments in Geant4. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2016, 835, 186-225.	1.6	2,327
49	The 68 Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq1 1	0,784314 0.7	rgBT /Overl
50	Brentuximab vedotin followed by ABVD +/â^' radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. Haematologica, 2016, 101, e139-e141.	3.5	12
51	18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia, 2016, 30, 417-422.	7.2	120
52	Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 414-421.	6.4	92
53	PET-Derived Metabolic Volume Metrics in the Hodgkin Lymphoma. , 2016, , 65-98.		Ο
54	Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial. Blood, 2016, 128, 992-992.	1.4	0

#	Article	lF	CITATIONS
55	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia, 2015, 29, 1360-1365.	7.2	57
56	PET-derived metabolic volume metrics in lymphoma. Clinical and Translational Imaging, 2015, 3, 331-341.	2.1	5
57	The Prognostic Role of Interim PET after First Chemotherapy Cycle and PET Sequential Evaluation of Response to ABVD in Hodgkin Lymphoma Patients - the Polish Lymphoma Research Group (PLRG) Observational Study. Blood, 2015, 126, 3943-3943.	1.4	5
58	Role of 123I-Iobenguane Myocardial Scintigraphy in Predicting Short-term Left Ventricular Functional Recovery: An Interesting Image. Journal of Clinical Imaging Science, 2015, 5, 56.	1.1	0
59	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica, 2014, 99, 1107-1113.	3.5	225
60	18Fluorine-fluorodeoxyglucose positron emission tomography/computed tomography total glycolytic volume in thymic epithelial neoplasms evaluation: a reproducible image biomarker. General Thoracic and Cardiovascular Surgery, 2014, 62, 228-233.	0.9	6
61	WIDEN: A tool for medical image management in multicenter clinical trials. Clinical Trials, 2014, 11, 355-361.	1.6	22
62	Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. a Pilot Phase II Study. Blood, 2014, 124, 3088-3088.	1.4	3
63	A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report Journal of Clinical Oncology, 2014, 32, 8507-8507.	1.6	5
64	International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers. Journal of Nuclear Medicine, 2013, 54, 683-690.	5.0	267
65	†ICD in Primary Prevention: Potential Role of Sympathetic Nerve Imaging'. The Open Cardiovascular Imaging Journal, 2013, 4, 1-3.	0.3	0
66	On-demand lung CT analysis with the M5L-CAD via the WIDEN front-end web interface and an OpenNebula-based cloud back-end. , 2012, , .		1
67	A method for the visual analysis of earlyâ€stage Parkinson's disease based on virtual MRIâ€derived SPECT images. International Journal of Imaging Systems and Technology, 2012, 22, 172-176.	4.1	2
68	Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial. Blood, 2012, 120, 550-550.	1.4	8
69	Dual-point FDG-PET: A novel scanning technique in Hodgkin lymphoma with bulky disease Journal of Clinical Oncology, 2012, 30, 8077-8077.	1.6	2
70	WIDEN: A tool for medical imaging management in oncology clinical trials Journal of Clinical Oncology, 2012, 30, e13093-e13093.	1.6	0
71	Early chemotherapy intensification with BEACOPP in advancedâ€stage Hodgkin lymphoma patients with a interimâ€PET positive after two ABVD courses. British Journal of Haematology, 2011, 152, 551-560.	2.5	127
72	Recent Improvements in Geant4 Electromagnetic Physics Models and Interfaces. Progress in Nuclear Science and Technology, 2011, 2, 898-903.	0.3	87

2

#	ARTICLE	IF	CITATIONS
73	Interim-PET Scan Interpretation In the Ongoing Prospective Clinical Trial HD 0607, In Advanced-Stage Hodgkin Lymphoma: Results of the the Expert Panel Review. Blood, 2010, 116, 3891-3891.	1.4	0
74	Comparative Assessment of Different Criteria for Interim-PET Interpretation in a Cohort of Hodgkin Lymphoma Patients Treated in a Single Center Blood, 2009, 114, 3657-3657.	1.4	0
75	Reversible impairment of coronary flow reserve in takotsubo cardiomyopathy: A myocardial PET study. Journal of Nuclear Cardiology, 2008, 15, 811-817.	2.1	52
76	Reversible impairment of coronary flow reserve in takotsubo cardiomyopathy: A myocardial PET study. Journal of Nuclear Cardiology, 2008, 15, 811-817.	2.1	5
77	Virtual MRI-derived SPECT for the visual analysis of Parkinson's disease in early stage. , 2008, , .		0
78	Myocardial scar and insulin resistance predict cardiovascular events in severe ischaemic myocardial dysfunction: a perfusion–metabolism positron emission tomography study. Nuclear Medicine Communications, 2008, 29, 448-454.	1.1	9
79	Benchmark of medical dosimetry simulation using the Grid. , 2007, , .		0
80	Evaluation of phase effects in Geant4 microdosimetry models for particle interactions in water. , 2007, , .		2
81	Microdosimetry in high-resolution cellular phantoms using the very low energy electromagnetic extension of the Geant4 toolkit. , 2007, , .		0
82	Correlation between delayed-enhancement magnetic resonance and nitrate myocardial Tc-99m tetrofosmin scintigraphy in myocardial infarction: a case report. Journal of Medical Case Reports, 2007, 1, 120.	0.8	2
83	Geant4 Physics Processes for Microdosimetry Simulation: Design Foundation and Implementation of the First Set of Models. IEEE Transactions on Nuclear Science, 2007, 54, 2619-2628.	2.0	86
84	Geant4 Model for the Stopping Power of Low Energy Negatively Charged Hadrons. IEEE Transactions on Nuclear Science, 2007, 54, 578-584.	2.0	6
85	Monte Carlo Simulation of Electromagnetic Interactions of Radiation with Liquid Water in the Framework of the Geant4-DNA Project. , 2006, , .		3
86	Atorvastatin Improves Myocardial Perfusion in a Patient With Hypercholesterolemia and Single-Vessel Coronary Disease. Clinical Nuclear Medicine, 2006, 31, 166-167.	1.3	0
87	Reversible inverse mismatch in transient left ventricular apical ballooning: Perfusion/metabolism positron emission tomography imaging. Journal of Nuclear Cardiology, 2006, 13, 587-590.	2.1	22
88	Geant4 developments and applications. IEEE Transactions on Nuclear Science, 2006, 53, 270-278.	2.0	4,869
89	Validation of Geant4 Bremsstrahlung models: first results. , 2006, , .		5

90 Geant4 model for the stopping power of low energy negatively charged hadrons. , 2006, , .

#	Article	IF	CITATIONS
91	Models of biological effects of radiation in the Geant4 Toolkit. , 2006, , .		2
92	Breath Control Device with EKG monitoring (ABCDE) for routine imaging and therapy. , 2006, , .		0
93	A powerful simulation tool for medical physics applications: Geant4. Nuclear Physics, Section B, Proceedings Supplements, 2003, 125, 80-84.	0.4	8
94	Monte Carlo dose calculation algorithm on a distributed system. Nuclear Physics, Section B, Proceedings Supplements, 2003, 125, 159-163.	0.4	3
95	Geant4—a simulation toolkit. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2003, 506, 250-303.	1.6	17,893
96	Feasibility of Intensity-Modulated Radiation Therapy in the Treatment of Advanced Cervical Chordoma. Tumori, 2003, 89, 298-304.	1.1	11
97	Radiomics in Malignant Lymphomas. , 0, , 71-82.		3
98	PET/CT Imaging of Lymphoma Outside the Western World. , 0, , 117-140.		1